Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Pavel Kapysh/Shutterstock.com Axsome Therapeutics (NASDAQ: AXSM ) stock is rising higher on Monday following an update from the FDA about product labeling. This update was announced in a filing with ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Epizyme (NASDAQ: EPZM ) stock is up nearly 65% today on news that the biotechnology company is going to be acquired by French pharmaceutical concern Ipsen (OTCMKTS: IPSEF ). A joint news release by the compani...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com We’re starting off the week with an overview of the biggest pre-market stock movers for Monday! Stocks are moving today on a reverse split, acquisition news, as well as a mon...
Transaction focused on lead asset Tazverik ® (tazemetostat), a first-in-class EZH2 a inhibitor approved in the U.S. Acquisition to bolster Ipsen’s growing oncology presence and leverage its infrastructure Ipsen to commence all-cash tender offer to...
Transaction focused on lead asset Tazverik ® (tazemetostat), a first-in-class EZH2 a inhibitor approved in the U.S. Acquisition to bolster Ipsen’s growing oncology presence and leverage its infrastructure Ipsen to commence all-cash tender offer to...
The definition of penny stocks is shares of companies trading below $5. But some of the most active traders in the stock market today focus on far cheaper issuers daily. Today we look at a few of the lowest-priced companies gaining attention. While there are many risks involved with stocks ...
Updated Activity Data from Phase 1b Portion of the Study Shows Continued Improvement in Both Objective and Complete Response Rates Update Includes Response Data for Sub-Group of Patients Who Are Rituximab-Refractory and with POD24 Epizyme, Inc. (Nasdaq: EPZM), a ...
Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that Grant Bogle, President and Chief Executive Officer, and Shefali Agarwa...
The following slide deck was published by Epizyme, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Epizyme, Inc. 2022 Q1 - Results - Earnings Call Presentation
Epizyme, Inc. (EPZM) Q1 2022 Earnings Conference Call May 10, 2022, 08:30 AM ET Company Participants Grant Bogle – President and Chief Executive Officer Shefali Agarwal - Senior Medical Adviser, Interim Chief Medical and Development Officer Joe Beaulieu - Senior Vice President, Head of...
News, Short Squeeze, Breakout and More Instantly...
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...